We are live on
!
Find out more
SCM
Sio Capital Management Portfolio holdings
AUM
$697M
1-Year Est. Return
79.73%
This Fund
S&P 500
This Quarter
Est. Return
+50.35%
1 Year Est. Return
+79.73%
3 Year Est. Return
+576.62%
5 Year Est. Return
+422.76%
10 Year Est. Return
+2,506.65%
AUM
$395M
AUM Growth
+$133M
(+51%)
Cap. Flow
+$73.6M
Cap. Flow
% of AUM
18.64%
Top 10 Holdings %
Top 10 Hldgs %
59.5%
Holding
66
New
14
Increased
6
Reduced
13
Closed
15
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Celcuity
CELC
|
+$31.5M |
| 2 |
Alkermes
ALKS
|
+$19M |
| 3 |
Sanofi
SNY
|
+$18.1M |
| 4 |
Kenvue
KVUE
|
+$17.2M |
| 5 |
Henry Schein
HSIC
|
+$15.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Globus Medical
GMED
|
+$14.5M |
| 2 |
Neurocrine Biosciences
NBIX
|
+$12.7M |
| 3 |
DRUG
Bright Minds Biosciences
DRUG
|
+$12.5M |
| 4 |
Annexon
ANNX
|
+$9.83M |
| 5 |
SEPN
Septerna Inc
SEPN
|
+$5.19M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 83.63% |
| 2 | Industrials | 12.89% |
| 3 | Consumer Staples | 3.47% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Humacyte Inc Warrant
HUMAW
$1.38M
| $12.2K | ﹤0.01% |
49,998
| – | – |
|
52
Alector
ALEC
$203M
| – | – |
-845,531
| Closed | -$1.18M |
|
|
53
Annexon
ANNX
$908M
| – | – |
-4,095,764
| Closed | -$9.83M |
|
54
Artivion
AORT
$1.29B
| – | – |
-158,736
| Closed | -$4.94M |
|
|
ATXS
55
DELISTED
Astria Therapeutics
ATXS
| – | – |
-318,256
| Closed | -$1.71M |
|
|
AVNS
56
DELISTED
Avanos Medical
AVNS
| – | – |
-288,849
| Closed | -$3.54M |
|
57
Embecta
EMBC
$208M
| – | – |
-31,169
| Closed | -$302K |
|
58
Enanta Pharmaceuticals
ENTA
$388M
| – | – |
-178,774
| Closed | -$1.35M |
|
|
59
Globus Medical
GMED
$11B
| – | – |
-245,570
| Closed | -$14.5M |
|
60
PUT
Idexx Laboratories
IDXX
$46.5B
| – | – |
-18,000
| Closed | -$9.65M |
|
61
PUT
INmune Bio
INMB
$50.8M
| – | – |
-1,299,300
| Closed | -$3M |
|
|
MRUS
62
DELISTED
Merus
MRUS
| – | – |
-62,719
| Closed | -$3.3M |
|
|
63
Neurocrine Biosciences
NBIX
$16.3B
| – | – |
-100,725
| Closed | -$12.7M |
|
64
Travere Therapeutics
TVTX
$5.88B
| – | – |
-122,210
| Closed | -$1.81M |
|
|
ATYR
65
PUT
aTyr Pharma
ATYR
$49.4M
| – | – |
-1,100
| Closed | -$5.58K |
|
|
MBX
66
MBX Biosciences
MBX
$3.2B
| – | – |
-241,000
| Closed | -$2.75M |
|
Similar funds
GUB
KLI
JA
AAM
TCM
CA
SAM
ACM
Sio Capital Management's Q3 2025 Portfolio in Review
As of Q3 2025, Sio Capital Management held 66 positions worth $395M, up 51% from $262M the previous quarter. Its ten largest holdings account for 60% of the portfolio.
Sio Capital Management deployed $73.6M of net new capital in Q3 2025, opening 14 new positions and adding to 6 existing holdings. Its largest new stake was Celcuity: 786,526 shares worth $38.9M.
By sector, the portfolio is most concentrated in Healthcare at 84% of assets, up from 80% a quarter earlier, followed by Industrials and Consumer Staples.
On the sell side, the largest reduction was Bright Minds Biosciences, an estimated $12.5M trimmed.
- Sio Capital Management's largest Q3 2025 buy was Celcuity: 786,526 shares worth $38.9M.
- Sio Capital Management added most to Sanofi in Q3 2025, an estimated $18.1M increase.
- Sio Capital Management's biggest Q3 2025 reduction was Bright Minds Biosciences, cutting an estimated $12.5M.
- Sio Capital Management fully exited Globus Medical in Q3 2025, selling an estimated $14.5M.
- Sio Capital Management's ten largest holdings make up 60% of its $395M portfolio in Q3 2025.
- Sio Capital Management opened 14 new positions and closed 15 in Q3 2025.
- Sio Capital Management's portfolio value rose 51% quarter-over-quarter to $395M.
Based on Sio Capital Management's 13F filing for Q3 2025, filed 13 Nov 2025.